Climb Bio (CLYM)

• Market cap: $205M
• 1 day: 30.43%
• 5 days: 73.41%
• 1 month: 56.25%
• 3 months: 33.33%
• 6 months: 134.38%
• Year to date: 44.93%
• 1 year: 6.38%
• 5 years: -81.13%
• 10 years: -81.13%
• Sector: Healthcare
• Industry: Biotechnology

About: Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. its product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the potential to treat a broad range of B-cell-mediated diseases.

Employees: 18